204 related articles for article (PubMed ID: 12750467)
1. Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate.
Winter-Vann AM; Kamen BA; Bergo MO; Young SG; Melnyk S; James SJ; Casey PJ
Proc Natl Acad Sci U S A; 2003 May; 100(11):6529-34. PubMed ID: 12750467
[TBL] [Abstract][Full Text] [Related]
2. Isoprenylcysteine carboxyl methyltransferase activity modulates endothelial cell apoptosis.
Kramer K; Harrington EO; Lu Q; Bellas R; Newton J; Sheahan KL; Rounds S
Mol Biol Cell; 2003 Mar; 14(3):848-57. PubMed ID: 12631708
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf.
Bergo MO; Gavino BJ; Hong C; Beigneux AP; McMahon M; Casey PJ; Young SG
J Clin Invest; 2004 Feb; 113(4):539-50. PubMed ID: 14966563
[TBL] [Abstract][Full Text] [Related]
4. Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells.
Bergo MO; Leung GK; Ambroziak P; Otto JC; Casey PJ; Young SG
J Biol Chem; 2000 Jun; 275(23):17605-10. PubMed ID: 10747846
[TBL] [Abstract][Full Text] [Related]
5. Genetic and pharmacologic analyses of the role of Icmt in Ras membrane association and function.
Svensson AW; Casey PJ; Young SG; Bergo MO
Methods Enzymol; 2006; 407():144-59. PubMed ID: 16757321
[TBL] [Abstract][Full Text] [Related]
6. Isoprenylcysteine Carboxyl Methyltransferase and Its Substrate Ras Are Critical Players Regulating TLR-Mediated Inflammatory Responses.
Yang WS; Kim HG; Kim E; Han SY; Aziz N; Yi YS; Kim S; Lee Y; Yoo BC; Han JW; Parameswaran N; Kim JH; Cho JY
Cells; 2020 May; 9(5):. PubMed ID: 32422978
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of isoprenylcysteine carboxylmethyltransferase sensitizes common chemotherapies in cervical cancer via Ras-dependent pathway.
Pan Q; Liu R; Banu H; Ma L; Li H
Biomed Pharmacother; 2018 Mar; 99():169-175. PubMed ID: 29331763
[TBL] [Abstract][Full Text] [Related]
8. Isoprenylcysteine carboxyl methyltransferase modulates endothelial monolayer permeability: involvement of RhoA carboxyl methylation.
Lu Q; Harrington EO; Hai CM; Newton J; Garber M; Hirase T; Rounds S
Circ Res; 2004 Feb; 94(3):306-15. PubMed ID: 14699010
[TBL] [Abstract][Full Text] [Related]
9. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells.
Winter-Vann AM; Baron RA; Wong W; dela Cruz J; York JD; Gooden DM; Bergo MO; Young SG; Toone EJ; Casey PJ
Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4336-41. PubMed ID: 15784746
[TBL] [Abstract][Full Text] [Related]
10. Isoprenylcysteine carboxylmethyltransferase regulates ovarian cancer cell response to chemotherapy and Ras activation.
Liu Q; Chen J; Fu B; Dai J; Zhao Y; Lai L
Biochem Biophys Res Commun; 2018 Jun; 501(2):556-562. PubMed ID: 29746868
[TBL] [Abstract][Full Text] [Related]
11. Isoprenylcysteine carboxylmethyltransferase is associated with nasopharyngeal carcinoma chemoresistance and Ras activation.
Zhu Y; Hu Q; Li H
Biochem Biophys Res Commun; 2019 Aug; 516(3):784-789. PubMed ID: 31253403
[TBL] [Abstract][Full Text] [Related]
12. Isoprenyl carboxyl methyltransferase inhibitors: a brief review including recent patents.
Yang WS; Yeo SG; Yang S; Kim KH; Yoo BC; Cho JY
Amino Acids; 2017 Sep; 49(9):1469-1485. PubMed ID: 28631011
[TBL] [Abstract][Full Text] [Related]
13. Adenosine dialdehyde suppresses MMP-9-mediated invasion of cancer cells by blocking the Ras/Raf-1/ERK/AP-1 signaling pathway.
Kim JH; Kim JH; Kim SC; Yi YS; Yang WS; Yang Y; Kim HG; Lee JY; Kim KH; Yoo BC; Hong S; Cho JY
Biochem Pharmacol; 2013 Nov; 86(9):1285-300. PubMed ID: 23994169
[TBL] [Abstract][Full Text] [Related]
14. An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo.
Lau HY; Ramanujulu PM; Guo D; Yang T; Wirawan M; Casey PJ; Go ML; Wang M
Cancer Biol Ther; 2014 Sep; 15(9):1280-91. PubMed ID: 24971579
[TBL] [Abstract][Full Text] [Related]
15. Isoprenylcysteine carboxyl methyltransferase promotes the progression of tongue squamous cell carcinoma via the K-Ras and RhoA signaling pathways.
Wang S; Wang W; Zhang S; Yang F; Qiu J; Guo Q; Zheng J; Chen Z
Arch Oral Biol; 2022 Feb; 134():105320. PubMed ID: 34875442
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of the integral membrane methyltransferase isoprenylcysteine carboxyl methyltransferase (ICMT) reveals potential substrate binding sites.
Diver MM; Long SB
J Biol Chem; 2014 Sep; 289(38):26007-26020. PubMed ID: 25059662
[TBL] [Abstract][Full Text] [Related]
17. Deficiency of Isoprenylcysteine Carboxyl Methyltransferase (ICMT) Leads to Progressive Loss of Photoreceptor Function.
Christiansen JR; Pendse ND; Kolandaivelu S; Bergo MO; Young SG; Ramamurthy V
J Neurosci; 2016 May; 36(18):5107-14. PubMed ID: 27147662
[TBL] [Abstract][Full Text] [Related]
18. NRAS is unique among RAS proteins in requiring ICMT for trafficking to the plasma membrane.
Ahearn IM; Court HR; Siddiqui F; Abankwa D; Philips MR
Life Sci Alliance; 2021 May; 4(5):. PubMed ID: 33579760
[TBL] [Abstract][Full Text] [Related]
19. Role of isoprenylcysteine carboxylmethyltransferase-catalyzed methylation in Rho function and migration.
Cushman I; Casey PJ
J Biol Chem; 2009 Oct; 284(41):27964-27973. PubMed ID: 19651782
[TBL] [Abstract][Full Text] [Related]
20. Isoprenylcysteine carboxyl methyltransferase is critical for glioblastoma growth and survival by activating Ras/Raf/Mek/Erk.
Wan W; Xiao W; Pan W; Chen L; Liu Z; Xu J
Cancer Chemother Pharmacol; 2022 Mar; 89(3):401-411. PubMed ID: 35171349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
